Welcome back to Plenary Session. This is the audio video edition. This is the paper you're

waiting for, Toclistamab. Now, before we get to Toclistamab, we've got to talk about the channel. This

is Plenary Session podcast. We've been going since 2018. We're the most popular oncology podcast

by a fair bit, and we talk about the clinical appraisal, the critical appraisal of clinical

trials on this channel for the most part. We also get into all sorts of evidence-based medicine and all

sorts of health care policy. Now, I'm like you. I'm listening to the audio feed, just like you

are at home. But I would encourage you, if you're listening to the audio feed, to get over to

video, just for my ASCO series, just for my ASCO series to get over to video just for my ASCO series just for my

ask go series get over to video i've got slides i've got visuals pictures worth a thousand words you want to be

on the video for this so move on over if you're listening to the audio feed i'll be back soon with more

audio content we'll be back with timothy olivier we're going to finish that malignant journal club

we've got a whole bunch more articles planned. People are sending me recommendations.

I've gotten more emails than I know what to do with about the topics we've covered. Let's just

review what we've covered so far on this channel. You can go back, but I'm hitting all the,

so far all the New England Journal medicine papers that came out during ASCO.

I did Shine.

I did Dynamic.

Well, Shine, of course, I wasn't a big fan of, and I think neither is a lot of people.

Then I did Dynamic.

I found some problems with that that I think actually flipped a few votes.

We did determination, as in we're determined to keep offering transplant and had some thoughts about that.

We did Destiny Breast 4, which, you know, I would have had more thoughts if I knew any of the pre-treatment or any of the post-treatment.

...